To evaluate the role of CXCL1 and CX3CL1 on the viability of RASMCs subjected to CMS, RASMCs were incubated with antagonists against CXCR2 and CX3CR1 and then subjected to CMS. This evidence concerns the gene CXCL1 and congenital myasthenic syndrome.